Erlotinib is marketed under the brand name Tarceva, and used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, it binds to the EGFR in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.
MARKET DYNAMICS
The erlotinib hydrochloride market is driving due to increasing cases of lung cancer worldwide. However, low adoption in low income countries is expected to hamper the growth of the global erlotinib hydrochloride market. Moreover, increasing early diagnosis is anticipated to drive demand the growth of the market.
MARKET SCOPE
The "Erlotinib Hydrochloride Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of erlotinib hydrochloride market with detailed market segmentation by type, application, and distribution channel. The erlotinib hydrochloride market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in erlotinib hydrochloride market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The erlotinib hydrochloride market is segmented based on type, application, and distribution channel. Based on type, the market is segmented into 25 mg, 100mg, and 150 mg. Based on application, the market is segmented into non-small cell lung cancer, and pancreatic cancer. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the erlotinib hydrochloride market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The erlotinib hydrochloride market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting erlotinib hydrochloride market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social, and technological factors effecting the Erlotinib Hydrochloride market in these regions.
MARKET PLAYERS
The report covers key developments in the erlotinib hydrochloride market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Erlotinib Hydrochloride market are anticipated to have lucrative growth opportunities in the future with the rising demand for erlotinib hydrochloride market in the global market. Below mentioned is the list of few companies engaged in the erlotinib hydrochloride market.
The report also includes the profiles of key players in erlotinib hydrochloride market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- F. Hoffmann-La-Roche AG
- Glenmark Pharmaceuticals
- Cipla
- Mylan N.V.
- Teva Pharmaceuticals
- Beacon Pharmaceuticals Limited
- Shilpa Medicare Ltd
- Sun Pharmaceutical Industries Ltd
- Cadila Healthcare
- Armas Pharmaceuticals Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.